Pharmaceutical Pricing Evidence From a Healthcare System With Multiple Cost-per-Quality-Adjusted Life-Year Thresholds
Value in Health · 2026
DOI: 10.1016/j.jval.2025.07.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026. Verfasst von Anton P H Klockhoff und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Östergötland, Sweden. Electronic address: anton.klockhoff@liu.se. Hauptthemen laut MEDLINE: Quality-Adjusted Life Years, Drug Costs. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council.
Abstract (Originalsprache)
OBJECTIVES: To study drug pricing in a reimbursement system accepting a higher cost per quality-adjusted life-year for drugs targeting conditions of higher severity. We investigate whether higher incremental cost-effectiveness ratios (ICERs) are observed for conditions of higher severity, how close to the highest acceptable cost-per-quality-adjusted life-year threshold drug prices are set, and whether the thresholds are applied as price ceilings. Furthermore, we explore factors other than severity that might affect pricing. METHODS: Disease severity and ICERs were extracted from publicly available reimbursement decisions made between 2017 and 2024 by the Swedish Dental and Pharmaceutical Benefits Agency. Linear regression assessed whether ICERs increase significantly with severity and other covariates and whether the same covariates explain deviations from the highest acceptable ICERs. We also assessed whether higher severity was associated with a higher likelihood of having confidential rebates in place. RESULTS: A total of 84 decisions reported ICERs and disease severity. ICERs increased significantly with severity (P < .01). The average ICER was 30.6% lower than the relevant threshold, and there was no evidence of pricing above the thresholds. Very high severity was associated with a 27.4% higher probability than moderate severity of the ICER including confidential rebates (P < .01). ICERs including rebates were associated with 19.1 percentage points smaller deviations from the threshold (P < .01). CONCLUSIONS: Prices tend to be set below the reimbursement system's thresholds and these appear to be ceilings, but decision makers should anticipate that drug companies will adjust prices in response to reimbursement policy, at least to some degree.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Östergötland, Sweden. Electronic address: anton.klockhoff@liu.se.
- Department of Management and Engineering, Linköping University, Linköping, Östergötland, Sweden.
- Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Östergötland, Sweden.
Förderung
- Swedish Research Council
Zitieren
APA
Klockhoff, A. P. H., Siverskog, J., & Henriksson, M. (2026). Pharmaceutical Pricing Evidence From a Healthcare System With Multiple Cost-per-Quality-Adjusted Life-Year Thresholds. Value in Health. https://doi.org/10.1016/j.jval.2025.07.027
Vancouver
Klockhoff APH, Siverskog J, Henriksson M. Pharmaceutical Pricing Evidence From a Healthcare System With Multiple Cost-per-Quality-Adjusted Life-Year Thresholds. Value in Health. 2026. doi:10.1016/j.jval.2025.07.027
BibTeX
@article{Klockhoff2026,
author = {Klockhoff, Anton P H and Siverskog, Jonathan and Henriksson, Martin},
title = {Pharmaceutical Pricing Evidence From a Healthcare System With Multiple Cost-per-Quality-Adjusted Life-Year Thresholds},
journal = {Value in Health},
year = {2026},
doi = {10.1016/j.jval.2025.07.027}
}
EUVIMED